Cargando…

Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Henkel, Jenny S, Beers, David R, Wen, Shixiang, Rivera, Andreana L, Toennis, Karen M, Appel, Joan E, Zhao, Weihua, Moore, Dan H, Powell, Suzanne Z, Appel, Stanley H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	WILEY-VCH Verlag 2013
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569646/ http://dx.doi.org/10.1002/emmm.201390002

Ejemplares similares

Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival
por: Henkel, Jenny S, et al.
Publicado: (2013)

Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis
por: Beers, David R., et al.
Publicado: (2011)

Clinical Significance of TDP-43 Neuropathology in Amyotrophic Lateral Sclerosis
por: Cykowski, Matthew D., et al.
Publicado: (2017)

Phosphorylated TDP-43 (pTDP-43) aggregates in the axial skeletal muscle of patients with sporadic and familial amyotrophic lateral sclerosis
por: Cykowski, Matthew D., et al.
Publicado: (2018)

Serum programmed cell death proteins in amyotrophic lateral sclerosis
por: Beers, David R., et al.
Publicado: (2021)

Fast Progression in Amyotrophic Lateral Sclerosis Is Associated With Greater TDP-43 Burden in Spinal Cord
por: Cathcart, Sahara J, et al.
Publicado: (2021)

Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis
por: Beers, David R., et al.
Publicado: (2020)

Blood–spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis
por: Winkler, Ethan A., et al.
Publicado: (2012)

TDP-43 pathology in the basal forebrain and hypothalamus of patients with amyotrophic lateral sclerosis
por: Cykowski, Matthew D, et al.
Publicado: (2014)

Combined Regulatory T-Lymphocyte and IL-2 Treatment Is Safe, Tolerable, and Biologically Active for 1 Year in Persons With Amyotrophic Lateral Sclerosis
por: Thonhoff, Jason R., et al.
Publicado: (2022)

Erratum to “Progress in Therapy Development for Amyotrophic Lateral Sclerosis”
por: Venkova-Hristova, Kalina, et al.
Publicado: (2012)

Erratum to: ADAMTS-4 promotes neurodegeneration in a mouse model of amyotrophic lateral sclerosis
por: Lemarchant, Sighild, et al.
Publicado: (2016)

ERRATUM: Effects of combined endurance and resistance training in Amyotrophic Lateral Sclerosis: A pilot, randomized, controlled study
por: Merico, Antonio, et al.
Publicado: (2018)

Use of sugammadex in a patient with progressive muscular atrophy and in a patient with amyotrophic lateral sclerosis: Case report: Erratum
Publicado: (2017)

Neutrophil-to-lymphocyte ratio in sporadic amyotrophic lateral sclerosis
por: Wei, Qian-Qian, et al.
Publicado: (2021)

Dipeptide repeat (DPR) pathology in the skeletal muscle of ALS patients with C9ORF72 repeat expansion
por: Cykowski, Matthew D., et al.
Publicado: (2019)

Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study
por: Thonhoff, Jason R., et al.
Publicado: (2018)

Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson’s disease
por: Thome, Aaron D., et al.
Publicado: (2021)

Tregs Attenuate Peripheral Oxidative Stress and Acute Phase Proteins in ALS
por: Beers, David R., et al.
Publicado: (2022)

Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability
por: Berry, James D., et al.
Publicado: (2017)

Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design
por: Berry, James, et al.
Publicado: (2021)

Amyotrophic lateral sclerosis
por: Wijesekera, Lokesh C, et al.
Publicado: (2009)

The Microglial-Motoneuron dialogue in ALS
por: APPEL, S.H., et al.
Publicado: (2011)

Senescent-like Blood Lymphocytes and Disease Progression in Amyotrophic Lateral Sclerosis
por: Yildiz, Ozlem, et al.
Publicado: (2022)

Protein aggregation in amyotrophic lateral sclerosis
por: Blokhuis, Anna M., et al.
Publicado: (2013)

Amyotrophic lateral sclerosis and neuroregeneration
Publicado: (2012)

Mimickers of Amyotrophic Lateral Sclerosis
por: Dubey, Ayush, et al.
Publicado: (2019)

Destination Amyotrophic Lateral Sclerosis
por: Keon, Matt, et al.
Publicado: (2021)

Prionoids in amyotrophic lateral sclerosis
por: Gosset, Philippe, et al.
Publicado: (2022)

Amyotrophic lateral sclerosis and cerebellum
por: Kabiljo, Renata, et al.
Publicado: (2022)

Dysautonomia in Amyotrophic Lateral Sclerosis
por: Oprisan, Alexandra L., et al.
Publicado: (2023)

Spinal Cord and Motor Neuron TDP-43 Pathology in a Sporadic Inclusion Body Myositis Patient
por: Cathcart, Sahara J, et al.
Publicado: (2020)

Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations
por: Lange, Dale J., et al.
Publicado: (2017)

Neutrophils-to-Lymphocyte Ratio Is Associated with Progression and Overall Survival in Amyotrophic Lateral Sclerosis
por: Leone, Maurizio A., et al.
Publicado: (2022)

Longitudinal biomarkers in amyotrophic lateral sclerosis
por: Huang, Fen, et al.
Publicado: (2020)

Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole
por: Corcia, Philippe, et al.
Publicado: (2012)

Extracellular Vesicles Derived From Ex Vivo Expanded Regulatory T Cells Modulate In Vitro and In Vivo Inflammation
por: Thome, Aaron D., et al.
Publicado: (2022)

SOD1 and Amyotrophic Lateral Sclerosis: Mutations and Oligomerization
por: Banci, Lucia, et al.
Publicado: (2008)

Functional alterations of myeloid cells during the course of Alzheimer’s disease
por: Thome, Aaron D., et al.
Publicado: (2018)

Potential Preventive Strategies for Amyotrophic Lateral Sclerosis
por: Kuraszkiewicz, B., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_evqrmjiuk796hcqf6ju720vfp8